an experimental antiviral drug to treat covid 19 patients has fanned high expectations in the fight against the coronavirus pandemic which has gained a decisive foothold in the united states and continues to spread around the world gilead sciences gild acknowledged wednesday that its drug remdisivir has seen positive results in both a company sponsored and national institute of health run study with the federal regulators reportedly prepared to bestow emergency approval on the drug according to the new york times the treatment has been a frontrunner in the treatment race for the global coronavirus pandemic after it was first tested in china which ended as enrollment numbers fell short however gilead s stock has mostly reaped the benefit of high expectations in a market desperate for good news despite skepticism about what early test results meant for a broader deployment strategy the study demonstrates the potential for some patients to be treated with a 5 day regimen which could significantly expand the number of patients who could be treated with our current supply of remdesivir dr merdad parsey gilead s chief medical officer said in a statement this is particularly important in the setting of a pandemic to help hospitals and healthcare workers treat more patients in urgent need of care she added the news sparked a market rally and amplified hopes for containing the global outbreak which has now claimed more than 3 1 million lives and killed more than 218 000 in the u s more than 1 million are now infected and killed more than 58 000 as officials debate how to safely relax lockdowns that are crippling the economy california is the latest state mulling a way to ease restrictions and companies are calling employees back to the offices in june yet the northeast remains a stronghold for growing cases and deaths with new york and new jersey seeing significant growth in infections despite falling hospitalization rates meanwhile massachusetts is also seeing increased rates of cases testing continues to be a major component of a reopening strategy as the centers for disease control eased restrictions on who can receive them the u s has now tested more than 5 7 million individuals with rhode island the top state in per capita testing followed by new york and new jersey gilead s study was a limited study of the effects of the drug on severe patients the study s results show similar positive outcomes in severe patients who were on the drug for either five days or 10 days the trial focused on patients who were not on ventilators and were given the drug within 10 days after the onset of symptoms at least 50 of patients were discharged from the hospital gilead said in its statement the results will still need to be peer reviewed but shows potential for the drug s ability to treat patients who are not on ventilators still the federal government appears to be moving quickly to capitalize on the results the u s food and drug administration is in talks with gilead to help boost drug production and get the drug to patients as quickly as possible as part of the fda s commitment to expediting the development and availability of potential covid 19 treatments the agency has been engaged in sustained and ongoing discussions with gilead sciences regarding making remdesivir available to patients as quickly as possible as appropriate the agency said in a statement meanwhile the results of a second placebo controlled probe by the nih s national institute of allergy and infectious disease will be announced at the white house coronavirus task force briefing later in the day gilead said wednesday they were informed of the positive results in the nih trial earlier in the month nih announced the drug was showing positive signs in repressing the virus in animal testing niaid director dr anthony fauci told reporters at the white house wednesday the nih study has shown results of improvements in patients but doesn t seem like a knock out and the robust study offers very important proof of concept the study showed a 31 improvement in recovery time for patients on remdisivir compared to those not taking the drug in addition the drug showed a reduction in deaths 8 versus 11 in the placebo group according to a statement from nih the first patient enrolled in the trial was a passenger on the diamond princess cruise ship which resulted in the first u s cases after passengers were repatriated in early february president donald trump also weighed in wednesday saying it s a very positive event click here for more of yahoo finance s coronavirus coverage personal finance tips news policy graphics more from yahoo finance anjalee khemlani is areporterat yahoo finance follow her on twitter anjkhem follow yahoo finance ontwitter facebook instagram flipboard linkedin andreddit find live stock market quotes and the latest business and finance news 